News Releases

2007

XXX
Dec.20,2007
Ono Enters into License Agreement with Nissan Chemical for New Therapeutic Agent for Thrombocytopenia (59.3KB)
XXX
Dec.12,2007
Announcement of JNDA Submission in Japan for SITAGLIPTIN,a New Oral Treatment of Type II Diabetes (29.2KB)
XXX
Nov.15,2007
Ono Enters into Service Agreement with Nissin for Use of New Carcinogenicity Evaluation System, Developed by Nissin, for Pharmaceutical Compounds (59.8KB)
XXX
Nov.08,2007
Revisions of Full Year Business Forecasts for FY 2007 (79.4KB)
XXX
Nov.05,2007
Ono Enteres Into New Drug Discovery Agreement on Kinases with Locus Pharmaceuticals, Inc. (76.9KB)
XXX
Oct.30,2007
Initiation of Development of “ONO-4538/MDX-1106ÂEFully Human Anti-PD-1 Antibody for Hepatitis C in US (19.3KB)
XXX
Oct.11,2007
Announcement on Completion of Acquisition of the Company's Own Shares (59.3KB)
XXX
Sep.28,2007
Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer's disease (100KB)
XXX
Aug.06,2007
Ono Enters into License Agreement with CeNeS Limited - New Intravenous Anaesthetic - (23.7KB)
XXX
Aug.06,2007
Announcement on Acquisition of the Company's Own Shares (60.6KB)
XXX
Jul.23,2007
Novartis Receives Recommendation for Approval of Patch Formulation of Exelon, Only Skin Patch for the Treatment of Alzheimer's Disease in EU (211KB)
XXX
Jul.10,2007
Novartis Receives First Worldwide Approval in US for Exelon Patch, the First and Only Skin Patch for the Treatment of Alzheimer's Disease (159KB)
XXX
Jul.05,2007
New Data Released at ADA Showed that Initial Combination Therapy with sitagliptin and Metformin Led to Significant Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes (Second Report) (75.5KB)
XXX
Jul.02,2007
Data Released at ADA showed efficacy in the Investigational use of a new oral medicine for type 2 diabetes, sitagliptin, and other medicine as Initial Combination Therapy (First Report) (73.9KB)
XXX
Jun.28,2007
Resolutions at the 59th Annual Shareholders Meeting (58.6KB)
XXX
Jun.20,2007
The Company Views and Policy on the Decrease in Number of Shares in One Trading Unit (48.4KB)
XXX
Jun.11,2007
Launch of Staybla® Tablets 0.1mg, a Drug for Overactive Bladder (59.9KB)
XXX
May.14,2007
Revision on Compensation for Members of the Board of Directors (48.7KB)
XXX
May.14,2007
The Company's Thoughts on the Shareholder Proposal (64.1KB)
XXX
Apr.18,2007
Announcement of Approval of Staybla®Tablets 0.1mg, a Drug for Overactive Bladder (51.7KB)
XXX
Apr.10,2007
Regarding Today's Media Report (51.0KB)
XXX
Apr.05,2007
Merck & Co, Inc. (Whitehouse Station, New Jersey, USA) Announced Approval of SITAGLIPTIN, a New Oral Treatment of Diabetes, in the European Union (115KB)
XXX
Mar.26,2007
Announcement on Cancellation of the Company's Own Shares (57.7KB)
XXX
Mar.26,2007
Announcement on Completion of Acquisition of the Company's Own Shares (59.4KB)
XXX
Feb.27,2007
Announcement of Establishment of Strategic Alliance Headquarters (61.1KB)
XXX
Feb.27,2007
Ono resolved increase in dividends projected for the fiscal year 2006(ending on March 31st,2007) (148KB)